| Literature DB >> 31219614 |
Nanxi Geng1, Yang Li1, Wenyu Zhang1, Fei Wang1, Xu Wang2, Zining Jin2, Yao Xing1, Danni Li3, Hongyan Zhang1, Yanshu Li1, Xiaodong Li1, Maosheng Cheng4, Feng Jin2, Feng Li1.
Abstract
Although clinically associated with the progression of multiple cancers, the biological function of p21-activated kinase 5 (PAK5) in breast cancer remains largely unknown. Here, we reveal that the PAK5-aspartyl aminopeptidase (DNPEP)-ubiquitin-specific protease 4 (USP4) axis is involved in breast cancer progression. We show that PAK5 interacts with and phosphorylates DNPEP at serine 119. Functionally, we demonstrate that DNPEP overexpression suppresses breast cancer cell proliferation and invasion and restricts breast cancer growth and metastasis in mice. Furthermore, we identify USP4 as a downstream target of the PAK5-DNPEP pathway; DNPEP mediates USP4 downregulation. Importantly, we verify that DNPEP expression is frequently downregulated in breast cancer tissues and is negatively correlated with PAK5 and USP4 expression. PAK5 decreases DNPEP abundance via the ubiquitin-proteasome pathway. Consistently, analyses of clinical breast cancer specimens revealed significantly increased PAK5 and USP4 levels and an association between higher PAK5 and USP4 expression and worse breast cancer patient survival. These findings suggest a pivotal role for PAK5-elicited signaling in breast cancer progression.Entities:
Keywords: DNPEP; PAK5; USP4; breast cancer progression; phosphorylation
Mesh:
Substances:
Year: 2019 PMID: 31219614 DOI: 10.1002/ijc.32523
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396